A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
NCT06033950
This study is recruiting at 54 US sites in 19 states, according to its ClinicalTrials.gov record last updated .
Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Colorado Prevention Center
- Last updated on ClinicalTrials.gov
- July 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- FIN-10004 Fairhope, AL Investigational Site · Fairhope, AL
Arizona · 2
- Phoenix, AZ Investigative Site FIN-10115 · Phoenix, AZ
- FIN-10401, Yuma, AZ · Yuma, AZ
California · 15
- Chula Vista, CA Investigative Site FIN-10111 · Chula Vista, CA
- Chula Vista, CA Investigative Site FIN-10419 · Chula Vista, CA
- FIN-10407, Northridge, CA · Northridge, CA
- FIN-10412, Orange, CA · Orange, CA
- FIN-10070, Pamona, CA · Pomona, CA
- FIN-10024, Sacramento, CA · Sacramento, CA
- FIN-10075 San Diego, CA Investigational Site · San Diego, CA
- FIN-10406, San Diego, CA · San Diego, CA
- San Diego, CA Investigative Site FIN-10420 · San Diego, CA
- San Francisco, CA Investigative Site FIN-10023 · San Francisco, CA
- FIN-10423, Sherman Oaks, CA · Sherman Oaks, CA
- FON-10409, Tarzana, CA · Tarzana, CA
- FIN-10109, Van Nuys, CA · Van Nuys, CA
- FIN-10408, West Covina, CA · West Covina, CA
- FIN-10013, West Hills, CA · West Hills, CA
Colorado · 2
- FIN-10001, Aurora, CO · Aurora, CO
- FIN-10110, Aurora, CO · Aurora, CO
Florida · 5
- Bradenton, FL Investigative Site FIN-10125 · Bradenton, FL
- FIN-10104, Hialeah, FL · Hialeah, FL
- FIN-10028, Jacksonville, FL · Jacksonville, FL
- FIN-10105, Miami, FL · Miami, FL
- FIN-10113, Miramar, FL · Miramar, FL
Illinois · 1
- FIN-10019, Peoria, IL · Peoria, IL
Indiana · 1
- FIN-10064, Merrillville, IN · Merrillville, IN
Kentucky · 6
- Cynthiana, KY Investigative Site FIN-10124 · Cynthiana, KY
- FIN-10080, Lexington, KY · Lexington, KY
- Lexington, KY Investigative Site FIN-10118 · Lexington, KY
- FIN-10086, Louisville, KY · Louisville, KY
- Louisville, KY Investigative Site FIN-10417 · Louisville, KY
- FIN-10079, Paducah, KY · Paducah, KY
Louisiana · 3
- FIN-10030, Baton Rouge, LA · Baton Rouge, LA
- FIN-10106, Hammond, LA · Hammond, LA
- FIN-10090, West Monroe, LA · West Monroe, LA
Minnesota · 1
- Minneapolis, MN Investigative Site FIN-10035 · Minneapolis, MN
Missouri · 1
- FIN-10002 Kansas City, MO Investigational Site · Kansas City, MO
North Carolina · 2
- FIN-10318, Charlotte, NC · Charlotte, NC
- Greenville, NC Investigative Site FIN-10122 · Greenville, NC
Ohio · 3
- FIN-10081, Akron, OH · Akron, OH
- FIN-10119, Centerville, OH · Centerville, OH
- FIN- 10112, Cincinnati, OH · Cincinnati, OH
South Carolina · 1
- Orangeburg, SC Investigative Site FIN-10433 · Orangeburg, SC
Texas · 4
- FIN-10015 Austin, TX Investigational Site · Austin, TX
- FIN-10404, Denison, TX · Denison, TX
- FIN-10085, Houston, TX · Houston, TX
- Tyler, TX Investigative Site FIN-10422 · Tyler, TX
Utah · 1
- FIN-10405, Layton, UT · Layton, UT
Vermont · 1
- FIN-10053, Burlington, VT · Burlington, VT
Virginia · 3
- FIN-10402, Norfolk, VA · Norfolk, VA
- FIN-10093, Richmond, VA · Richmond, VA
- Salem, VA Investigative Site FIN-10048 · Salem, VA
Wisconsin · 1
- Milwaukee, WI Investigative Site FIN-10428 · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.